<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2019-08-01" updated="2019-11-02">
  <drugbank-id primary="true">DB15466</drugbank-id>
  <name>Tallimustine</name>
  <description>Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.[A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of Î±-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity/myelotoxicity ratio.[A182039,A182045] Newer generations of DNA minor groove binding agents can more specifically recognize base pair sequences.[A182051]</description>
  <cas-number>115308-98-0</cas-number>
  <unii>71193OXG6S</unii>
  <average-mass>697.62</average-mass>
  <monoisotopic-mass>696.2454551</monoisotopic-mass>
  <groups>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A182036</ref-id>
        <pubmed-id>11772279</pubmed-id>
        <citation>Marchini S, Broggini M, Sessa C, D'Incalci M: Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14. doi: 10.1517/13543784.10.9.1703 .</citation>
      </article>
      <article>
        <ref-id>A182039</ref-id>
        <pubmed-id>12620417</pubmed-id>
        <citation>Cozzi P: The discovery of a new potential anticancer drug: a case history. Farmaco. 2003 Mar;58(3):213-20. doi: 10.1016/S0014-827X(03)00014-4.</citation>
      </article>
      <article>
        <ref-id>A182045</ref-id>
        <pubmed-id>10919073</pubmed-id>
        <citation>Cozzi P: Recent outcome in the field of distamycin-derived minor groove binders. Farmaco. 2000 Mar;55(3):168-73.</citation>
      </article>
      <article>
        <ref-id>A182048</ref-id>
        <pubmed-id>17691953</pubmed-id>
        <citation>Lauria A, Montalbano A, Barraja P, Dattolo G, Almerico AM: DNA minor groove binders: an overview on molecular modeling and QSAR approaches. Curr Med Chem. 2007;14(20):2136-60.</citation>
      </article>
      <article>
        <ref-id>A182051</ref-id>
        <pubmed-id>30866557</pubmed-id>
        <citation>Paul A, Guo P, Boykin DW, Wilson WD: A New Generation of Minor-Groove-Binding-Heterocyclic Diamidines That Recognize G.C Base Pairs in an AT Sequence Context. Molecules. 2019 Mar 7;24(5). pii: molecules24050946. doi: 10.3390/molecules24050946.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Cozzi P: The discovery of a new potential anticancer drug: a case history. Farmaco. 2003 Mar;58(3):213-20. doi: 10.1016/S0014-827X(03)00014-4.</synthesis-reference>
  <indication>Tallimustine was being investigated for its use in treating tumors.[A182036,A182039] Derivatives of tallimustine with similar DNA binding ability and reduced myelotoxicity are being investigated for their antitumor activity.[A182039]</indication>
  <pharmacodynamics/>
  <mechanism-of-action>Tallimustine binds to the minor groove of DNA while avoiding targets like glutathione.[A182039] Currently, the mechanism of DNA minor groove binding agents is poorly understood.[A182048] Though, they may act by directly inhibiting the interaction of protein and DNA.[A182048]</mechanism-of-action>
  <toxicity>Tallimustine is associated with myelotoxicity severe enough to stop its development.[A182036,A182039]</toxicity>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002880</drugbank-id>
      <name>Tallimustine hydrochloride</name>
      <unii>JWV8AC9E4V</unii>
      <cas-number>118438-45-2</cas-number>
      <inchikey>BLSOATWWAGIRGE-UHFFFAOYSA-N</inchikey>
      <average-mass>734.08</average-mass>
      <monoisotopic-mass>732.2221329</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn">Tallimustine</synonym>
  </synonyms>
  <products/>
  <international-brands/>
  <mixtures/>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Alkylating Drugs</category>
      <mesh-id>D000477</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents</category>
      <mesh-id>D000970</mesh-id>
    </category>
    <category>
      <category>Antineoplastic Agents, Alkylating</category>
      <mesh-id>D018906</mesh-id>
    </category>
    <category>
      <category>Hydrocarbons, Halogenated</category>
      <mesh-id>D006846</mesh-id>
    </category>
    <category>
      <category>Mustard Compounds</category>
      <mesh-id>D009150</mesh-id>
    </category>
    <category>
      <category>Noxae</category>
      <mesh-id>D009676</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Toxic Actions</category>
      <mesh-id>D004786</mesh-id>
    </category>
  </categories>
  <affected-organisms/>
  <dosages/>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00012</drugbank-id>
      <name>Darbepoetin alfa</name>
      <description>The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tallimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00016</drugbank-id>
      <name>Erythropoietin</name>
      <description>The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tallimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08894</drugbank-id>
      <name>Peginesatide</name>
      <description>The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tallimustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09107</drugbank-id>
      <name>Methoxy polyethylene glycol-epoetin beta</name>
      <description>The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tallimustine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>2.6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>5.43e-02 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.41</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-{4-[bis(2-chloroethyl)amino]benzamido}-N-[5-({5-[(2-carbamimidoylethyl)carbamoyl]-1-methyl-1H-pyrrol-3-yl}carbamoyl)-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>4-{4-[bis(2-chloroethyl)amino]benzamido}-N-[5-({5-[(2-carbamimidoylethyl)carbamoyl]-1-methylpyrrol-3-yl}carbamoyl)-1-methylpyrrol-3-yl]-1-methylpyrrole-2-carboxamide</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>697.62</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>696.2454551</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC(=O)C4=CC=C(C=C4)N(CCCl)CCCl)=CN3C)=CN2C)C=C1C(=O)NCCC(N)=N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C32H38Cl2N10O4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C32H38Cl2N10O4/c1-41-18-22(14-25(41)30(46)37-11-8-28(35)36)39-32(48)27-16-23(19-43(27)3)40-31(47)26-15-21(17-42(26)2)38-29(45)20-4-6-24(7-5-20)44(12-9-33)13-10-34/h4-7,14-19H,8-13H2,1-3H3,(H3,35,36)(H,37,46)(H,38,45)(H,39,48)(H,40,47)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>ARKYUICTMUZVEW-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>184.3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>203.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>76.45</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>15</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>15.03</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>12.56</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>59332</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL89705</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004796</id>
      <name>DNA</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A182036</ref-id>
            <pubmed-id>11772279</pubmed-id>
            <citation>Marchini S, Broggini M, Sessa C, D'Incalci M: Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14. doi: 10.1517/13543784.10.9.1703 .</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>